Application of Mixed Reality Technique for Percutaneous Lung Nodule Localization: A Prospective, Randomized, Controlled Trial

Lung Cancer Clinical Trial

— MR  

Official title:

Application of Mixed Reality Technique for Percutaneous Lung Nodule Localization: A Prospective, Randomized, Controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05715996
• Other study ID #: ShanghaiChestMR
• Status: Recruiting
• Phase: N/A
• Start date: May 23, 2023
• Est. completion date: March 2024

Study information

• Verified date: November 2023
• Source: Shanghai Chest Hospital
• Contact: Xinghua Cheng, MD
• Phone: +8617701681215
• Email: chengxinghua_001[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

With the popularization of CT screening, the detection rate of small lung nodules has greatly increased. Therefore, the clinical thoracoscopic lung nodule biopsy and sub-lobectomy for radical resection of lung cancer are greatly required. Accurate resection of lung nodule depends on precise localization of pulmonary nodules. However, preoperative CT-guided Hook- wire positioning under local anesthesia, which is the current primary localization method, requires high equipment and expense, and may cause physical and mental trauma to the patient. Augmented reality (AR) is an innovative technology that superimpose a virtual scene into the real environment by fusing images, videos, or computer-generated models with patients during surgical operations. It can visually display the anatomical structures of organs or lesions, which significantly improves surgical efficiency. This project intends to use AR technology to localize the solitary pulmonary nodule (SPN) before surgery, compared with CT-guided Hook-wire localization. Compared with the localization of SPNs under CT guidance, AR-assisted localization technology apparently is less time-consuming and can be performed immediately before surgery under general anesthesia, lessening pain, reduce costs of time and equipment, increase the success rate of sub-lobectomy, and improve the overall efficiency of surgical treatment of pulmonary nodules.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 74
• Est. completion date: March 2024
• Est. primary completion date: March 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Male or female = 18years of age;

2. There was no distant metastasis in preoperative clinical evaluation;

3. The attending physician evaluated and confirmed the need for lung nodule localization and sub-lobectomy;

4. Target lung nodule diameter = 2cm

5. The inner edge of the target node is at least 2 cm from the pulmonary artery or pulmonary vein

6. preoperative ECOG physical state score 0/1;

7. Volunteer to participate in the study and sign the informed consent form.

Exclusion Criteria:

1. More than two lung nodules need to be removed at the same time.

2. The target node is located in the scapular region. Because percutaneous localization is obstructed by the scapula, percutaneous localization of pulmonary nodules is not suitable for such patients.

3. The patient has uncontrollable mental illness and cannot make subjective assessment.

4. After being selected, severe complications (unable to tolerate surgery or anesthesia) occurred before operation are not suitable or the treatment plan of the study cannot be implemented as planned;

5. After being selected, the patient's condition changes and needs to be changed from elective surgery to emergency surgery after being confirmed by the competent doctor;

6. At any stage after entering the study, the patient voluntarily requests to withdraw or discontinue treatment due to personal reasons.

Related Conditions & MeSH terms

• Lung Cancer

Intervention

Device:
• mixed reality guided localization
In this study, MR was utilized to assist in the localization of pulmonary nodule during sublobectomy lung resection in patient to assess the accuracy of the technique.

Locations

Country	Name	City	State
China	Zuodong Song	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Chest Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Accuracy of nodule localization	The deviation between the local quantizer and the target nodule center was evaluated. The deviation is expressed as vertical deviation, anteroposterior deviation and horizontal deviation in three dimensions. The total deviation of nodule localization is calculated as the square root of the sum of squares of each dimension.	30 minutes
Secondary	Operation duration	Since the start/end point of CT-guided pulmonary nodule localization may be arbitrary and there may be differences between different researchers, the program duration is derived from the CT scanning parameters and calculated as the length of time between the initial scan and the final scan. The hybrid reality guided positioning time is automatically recorded by the system from the beginning of registration to the completion of positioning	30 minutes
Secondary	Incidence of complications	Including pneumothorax, hemoptysis, circulation changes caused by bleeding, pleural reaction, etc	7 days
Secondary	Radiation exposure dose	The dose length product (DLP) was used to quantify the total radiation received by patients during the localization of pulmonary nodules. In addition, after the scanning process, the DLP value is directly displayed on the screen of the CT scanner. In order to estimate the relative amount of radiation dose, the effective dose (ED) is also calculated according to the DLP value	30 minutes
Secondary	Postoperative puncture pain assessment	On the first day after the operation, when the patient was fully awake, the pain degree of the patient during the positioning process was evaluated by using the NRS (digital scoring method) and the Digital Assessment Scale of Pain Degree. The degree of pain is expressed in 0-10 numbers, 0 means no pain, and 10 means the most severe pain. It is left to the patient to choose a number that best represents the degree of pain, and the medical staff will select the corresponding number according to the patient's description of pain. According to the corresponding number of pain, the pain degree is divided into mild pain (1-3), moderate pain (4-6), and severe pain (7-10)	7 days